Regulatory FDA hands another rejection to Replimune’s melanoma therapy PharmaphorumReplimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.RegulatoryOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaphorum Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses. RegulatoryOncologyRead full story Post navigation Previous: Bayer wins MHRA approval for Kerendia in heart failureNext: FDA issues complete response letter to Replimune’s RP1 for melanoma Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
